| Trial ID: | L4456 |
| Source ID: | NCT00816218
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Molecular Mechanisms of Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Pioglitazone
|
| Outcome Measures: |
Primary: Vascular Endothelial Function, Brachial arterial dilation and blood flow, at 3 , 6 and 9 months post-therapy | Secondary: Insulin Resistance, Inmsulin-mediated glucose disposal, Basal and 9 months
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: Takeda
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2003-03
|
| Completion Date: |
2008-11
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-31
|
| Locations: |
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00816218
|
